David Gray
Company: Vigil Neuroscience
Job title: Chief Scientific Officer
Seminars:
The Next Generation of Alzheimer’s Treatment: Harnessing Microglia with TREM2 Agonism 1:30 pm
Harnessing neuroprotective microglial states for the next generation of AD treatment Potent small molecule TREM2 agonists that act as molecular glues to stabilize a multimeric signalling complex Genetic and biomarker strategies to aid early development and how a small molecule TREM2 agonist may address unmet needs in ADRead more
day: Clinical & Commercial Track Day 2 PM
Panel Discussion: How Will Diagnostics Change With the NIA-AA Revised Criteria for Diagnosis & Staging of Alzheimer’s Disease? 5:30 pm
Shifting Alzheimer’s Disease definitions to more biological than clinical definitions Integrating the latest validated findings in plasma-based marker research to establish likelihood of developing AD Exploring how the novel staging might affect diagnosis and staging to understand the potential impact on clinical researchRead more
day: Conference Day One